Sentiment Trading

Valneva SE, a French biotechnology company, navigated a challenging year with opportunities for growth, despite financial losses and regulatory hurdles, as it continues to develop vaccines for infectious diseases.

The European Medicines Agency (EMA) has lifted its temporary restriction on Valneva’s chikungunya vaccine, IXCHIQ, for individuals aged 65 and above, allowing its use in vulnerable populations.